A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.

Trial Profile

A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Cangrelor (Primary) ; Prasugrel
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Pharmacodynamics
  • Sponsors The Medicines Company
  • Most Recent Events

    • 09 Oct 2013 Study completion announced in a media release issued by The Medicines Company.
    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top